Gene therapy: progress in childhood disease.
The recent sequencing of the human genome combined with the development of massively high throughput genetic analysis technologies is driving unprecedented growth in our knowledge of the molecular basis of disease. While this has already had a major impact on our diagnostic power, the therapeutic benefits remain largely unrealised. This review examines progress in the exciting and challenging field of gene therapy. In particular we focus on the treatment of genetic disease in infants and children where the most significant successes have been observed to date, despite the majority of trial participants being adults. Notably, gene transfer to the haematopoietic compartment has provided the clearest examples of therapeutic benefit, particularly in the context of primary immunodeficiencies. The triumphs and tribulations of these successes are explored, and the key challenges confronting researchers as they seek to further advance the field are defined and discussed.
Gene Therapy Research Unit, Children's Medical Research Institute and The Children's Hospital at Westmead, Australia.
Samantha L
SL
Ginn
Ian E
IE
Alexander
D000243:Adenosine Deaminase / Q000172:deficiency; D000361:Agammaglobulinemia / Q000628:therapy; D002648:Child; D015316:Genetic Therapy / Q000009:adverse effects / Q000941:ethics / Q000379:methods / Q000639:trends; D006801:Humans; D057130:Leber Congenital Amaurosis / Q000628:therapy; D016511:Severe Combined Immunodeficiency / Q000628:therapy; D014923:Wiskott-Aldrich Syndrome / Q000628:therapy; D053632:X-Linked Combined Immunodeficiency Diseases / Q000628:therapy
D000243:Adenosine Deaminase